請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71771
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳為堅 教授(Wei-Jane Chen) | |
dc.contributor.author | Iddrisu Bukari | en |
dc.contributor.author | 尹得利 | zh_TW |
dc.date.accessioned | 2021-06-17T06:09:15Z | - |
dc.date.available | 2021-02-23 | |
dc.date.copyright | 2021-02-23 | |
dc.date.issued | 2021 | |
dc.date.submitted | 2021-02-19 | |
dc.identifier.citation | Agrawal, Y., Platz, E. A., Niparko, J. K. (2008). Prevalence of hearing loss and differences by demographic characteristics among US adults: data from the National Health and Nutrition Examination Survey, 1999-2004. Archives of internal medicine, 168(14),1522 Amedofu, G. K., Brobby, G. W., Ocansey, G. (1997). The causes and prevalence of preschool deafness in Ghana. African journal of health sciences, 4(1), 29-32. Amedofu, G. K., Ocansey, G., Antwi, B. B. (2005). Characteristics of hearing-impairment among patients in Ghana. African journal of health sciences, 12(3), 87-93. Ashtiani, M. K., Firouzi, F., Bastaninejad, S., Dabiri, S., Nasirmohtaram, S., Saeedi, N., ... Sahebi, L. (2018). Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic suddensensorineural hearing loss: a randomized controlled trial. European Archives of OtoRhino-Laryngology, 275(1), 89-97. Bernasconi, V., Kristiansen, P. A., Whelan, M., Román, R. G., Bettis, A., Yimer, S. A., ... Kumar, A. (2020). Developing vaccines against epidemic-prone emerging infectious diseases. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz, 63(1). Bloch, A. (1978). A serological survey of Lassa fever in Liberia. Bulletin of the World Health Organization, 56(5), 811. Branco, L. M., Grove, J. N., Boisen, M. L., Shaffer, J. G., Goba, A., Fullah, M., ... Garry, R. F. (2011). Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virology journal, 8(1), 478. Centers for Disease Control and Prevention. Lassa fever. CDC Fact Sheet https://www.cdc.gov/vhf/lassa/pdf/factsheet.pdf [accessed: December 07, 2018].38 Centers for Disease Control and Prevention. Lassa fever. CDC Fact Sheet https://www.cdc.gov/vhf/lassa/pdf/factsheet.pdf [accessed: April 5, 2020] Centers for Disease Control, Prevention (US), National Center for Infectious Diseases (US). (1994). Addressing emerging infectious disease threats: a prevention strategy for the United States. Chandrasekhar, S. S., Tsai Do, B. S., Schwartz, S. R., Bontempo, L. J., Faucett, E. A., Finestone, S. A., ... Satterfield, L. (2019). Clinical practice guideline: sudden hearing loss (update). Otolaryngology–Head and Neck Surgery, 161(1_suppl), S1-S45. Chau, J. K., Cho, J. J., Fritz, D. K. (2012). Evidence-based practice: management of adult sensorineural hearing loss. Otolaryngologic clinics of North America, 45(5), 941-958. Chau, J. K., Lin, J. R., Atashband, S., Irvine, R. A., Westerberg, B. D. (2010). Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. The Laryngoscope, 120(5), 1011-1021. Clegg, J. C. S., Lloyd, G. (1987). Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. The Lancet, 330(8552),18 Dror, A. A., Avraham, K. B. (2009). Hearing loss: mechanisms revealed by genetics and cell biology. Annual review of genetics, 43, 411-437. Eze, K. C., Salami, T. A. T., Eze, I. C., Pogoson, A. E., Omordia, N., Ugochukwu, M. O.(2010). High Lassa Fever activity in northern part of Edo State, Nigeria: reanalysis of confirmatory test results. African Journal of Health Sciences, 17(3 4), 52-56. Fichet-Calvet, E., Rogers, D. J. (2009). Risk maps of Lassa fever in West Africa. PLoS neglected tropical diseases, 3(3).39 Fisher-Hoch, S. P., McCormick, J. B. (2004). Lassa fever vaccine. Expert review of vaccines, 3(2), 189-197 Frame, J. D., Baldwin Jr, J. M., Gocke, D. J., Troup, J. M. (1970). Lassa fever, a new virus disease of man from West Africa. The American journal of tropical medicine and hygiene, 19(4), 670-676. Hallam, H. J., Hallam, S., Rodriguez, S. E., Barrett, A. D., Beasley, D. W., Chua, A., ... Reece, L. M. (2018). Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. Npj Vaccines, 3(1), 1-12. Health Quality Ontario. (2018). Continuous monitoring of glucose for type 1 diabetes: a health technology assessment. Ontario health technology assessment series, 18(2), 1. Hojjat, H., Svider, P. F., Davoodian, P., Hong, R. S., Folbe, A. J., Eloy, J. A., A. Shkoukani, M. (2017). To image or not to image? A cost‐effectiveness analysis of MRI for patients with asymmetric sensorineural hearing loss. The Laryngoscope, 127(4),939 Hone, S. W., Smith, R. J. (2001, December). Genetics of hearing impairment. In Seminars in Neonatology (Vol. 6, No. 6, pp. 531-541). WB Saunders. Houlihan, C., Behrens, R. (2017). Lassa fever. Bmj, 358, j2986. https://epi.tghn.org/vaccine-development/vaccine-safety/ Huy, P. T. B., Sauvaget, E. (2005). Idiopathic sudden sensorineural hearing loss is not an otologic emergency. Otology Neurotology, 26(5), 896-902. Jiang, X., Dalebout, T. J., Bredenbeek, P. J., Carrion Jr, R., Brasky, K., Patterson, J., ... GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine, 29(6), 1248-1257.40 Khan, S. H., Goba, A., Chu, M., Roth, C., Healing, T., Marx, A., ... Monagin, C. (2008). New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral research, 78(1), 103-115. Lentz, J. J. (2018). Psychoacoustics: perception of normal and impaired hearing with audiology applications. Plural Publishing. Löhler, J., Walther, L. E., Hansen, F., Kapp, P., Meerpohl, J., Wollenberg, B., ... Schmucker, C. (2019). The prevalence of hearing loss and use of hearing aids among adults in Germany: a systematic review. European Archives of Oto-RhinoLaryngology, 276(4), 945-956. Lukashevich, I. S. (2012). Advanced vaccine candidates for Lassa fever. Viruses, 4(11), Lukashevich, I. S., Patterson, J., Carrion, R., Moshkoff, D., Ticer, A., Zapata, J., ... Salvato, M. S. (2005). A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. Journal of virology, 79(22), 13934-13942. Mateer, E. J., Huang, C., Shehu, N. Y., Paessler, S. (2018). Lassa fever–induced sensorineural hearing loss: a neglected public health and social burden. PLoS neglected tropical diseases, 12(2). McCormick, J. B., Fisher-Hoch, S. P. (2002). Lassa fever. In Arenaviruses I (pp. 75-109). Springer, Berlin, Heidelberg. McCormick, J. B., King, I. J., Webb, P. A., Scribner, C. L., Craven, R. B., Johnson, K. M., ... Belmont-Williams, R. (1986). Lassa fever. New England Journal of Medicine, 314(1), 20-26. McPherson, B. (2014). Hearing assistive technologies in developing countries: background, achievements and challenges. Disability and Rehabilitation: Assistive Technology, 9(5)41 Mylne, A. Q., Pigott, D. M., Longbottom, J., Shearer, F., Duda, K. A., Messina, J. P., ... Hay, S. I. (2015). Mapping the zoonotic niche of Lassa fever in Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 109(8), 483-492. Morton NE. Genetic epidemiology of hearing impairment. Ann N Y Acad Sci 1991; 630:16-3 Ogbu, O., Ajuluchukwu, E., Uneke, C. J. (2007). Lassa fever in West African sub-region: an overview. Journal of vector borne diseases, 44(1). Olusanya, B. O., Neumann, K. J., Saunders, J. E. (2014). The global burden of disabling hearing impairment: a call to action. Bulletin of the World Health Organization, 92,367 Ouyang, X. M., Yan, D., Yuan, H. J., Pu, D., Du, L. L., Han, D. Y., Liu, X. Z. (2009). The genetic bases for non-syndromic hearing loss among Chinese. Journal of human genetics, 54(3), 131. Richmond, J. K., Baglole, D. J. (2003). Lassa fever: epidemiology, clinical features, and social consequences. Bmj, 327(7426), 1271-1275. Ridley, C. L., Kopun, J. G., Neely, S. T., Gorga, M. P., Rasetshwane, D. M. (2018). Using thresholds in noise to identify hidden hearing loss in humans. Ear and hearing, 39(5),8 Rybak, L. P. (1990). Deafness associated with Lassa fever. Jama, 264(16), 2119-2119. Safronetz, D., Mire, C., Rosenke, K., Feldmann, F., Haddock, E., Geisbert, T., Feldmann, H. (2015). A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS neglected tropical diseases, 9(4). Shargorodsky, J., Curhan, S. G., Curhan, G. C., Eavey, R. (2010). Change in prevalence of hearing loss in US adolescents. Jama, 304(7), 772-778.42 Sogoba, N., Feldmann, H., Safronetz, D. (2012). Lassa fever in West Africa: evidence for an expanded region of endemicity. Zoonoses and public health, 59, 43-47. Son, E. J., Bang, J. H., Kang, J. G. (2007). Anterior inferior cerebellar artery infarction presenting with sudden hearing loss and vertigo. The Laryngoscope, 117(3), 556-558. Troup, J. M., White, H. A., Fom, A. L., Carey, D. E. (1970). An Outbreak of Lassa Fever on the Jos Plateau, Nigeria, in January–February 1970. The American journal of tropical medicine and hygiene, 19(4), 695-696. Ungar, O. J., Wengier, A., Cavel, O., Handzel, O., Oron, Y. (2020). Hearing improvement after sudden sensorineural hearing loss as a predictor of vestibular schwannoma. ORL, 82(1), 53-58. Wilson, B. S., Tucci, D. L., Merson, M. H., O'Donoghue, G. M. (2017). Global hearing health care: new findings and perspectives. The Lancet, 390(10111), 2503-2515. WHO World Report on Disability (2011), a review. Disability and health journal, 4(3), 141-142. World Health Organization. (2008). The global burden of disease: 2004 update. World Health Organization. (2017). WHO target product profile for Lassa virus Vaccine. Lassa fever R D http://www. who. int/blueprint/priority diseases/keyaction/LassaVirusVaccineTPP. PDF. World Health Organization. (2018). List of Blueprint priority diseases. Cambridge: WHO.(accessed on January 28, 2019). World Health Organization. Lassa fever fact sheet 2016. Online at http://www. who.int/mediacentre/factshe ets/fs179/en. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71771 | - |
dc.description.abstract | 背景:听力损失已被列为世界范围内残疾年龄排名第四的主要因素,这是一个沉默寡言的,报告不足的公共健康问题,在财务和社会生活上有许多不利因素。这在发展中国家的贫困弱势人群中最明显,那里有80%的听力损失者居住。世卫组织预测,到2050年,将有9亿多人遭受各种形式的听力损失。 目的:本研究使用布莱顿协作标准病例定义评估了加纳成年人口的感音神经性听力丧失(SNHL)的诊断。 方法:本研究设计是一项回顾性研究方法,旨在对加纳的科莫·安诺克耶教学医院眼耳鼻喉科的SNHL患者的诊断进行回顾性研究,这些患者年龄从18岁到59岁不等。基于Brighton Collaboration标准案例定义的2018年1月至2020年6月。 结果:本研究的300名参与者中,男性165名,女性135名。 根据BC病例分类,SNHL在300例患者中的诊断确定性水平分布在三个分类水平上。 (L1)253级(84.3%),2级(L2)2级(0.6%)和4级(L4)45级(15%),在300例中,有45例无法分类(4级)。当将男性和女性分开时,总体数据显示,男性患者的1级百分比较低,而4级的百分比高于女性。当分别来自不同来源的患者出现时,手动数据患者的诊断确定性水平的男女差异是相同的,但对于电子数据患者则无显着性。 比较了来自人工数据的患者的两种数据来源的SNHL诊断确定性水平的分布,其中电子数据的患者具有较高的1级百分比和较低的4级百分比。 结论:根据这项研究的结果,可以很好地确定BC标准病例定义适用于加纳的三级医院。数据证据表明,大多数病例是在1级诊断。这可能意味着在加纳和其他西非国家的三级医院中,可以满足BC标准,并且大多数诊断将在BC标准定义之内。 。但是,八项关键要素考试中有四项是:没有可用的脑干反应,耳声发射异常,行为/神经发育评估异常和远程筛查异常,因此,医院管理部门必须努力建立基础设施来满足此类需求。 | zh_TW |
dc.description.abstract | Background: Hearing loss has been ranked as the fourth leading contributor to years lived with disability worldwide and this is a silent and under-reported public health problem with numerous financial and social life disadvantages. This is mostly visible among poor vulnerable populations in developing countries where more than eighty percent of people with hearing loss reside. The WHO projects in the year 2050 more than 900 million people will be suffering from various forms of hearing loss. Aim: This study evaluated the diagnosis of sensorineural hearing loss (SNHL) in the adult population of Ghana using the Brighton Collaboration standard case definition. Methods: The research design was a retrospective study approach, conducted to review the diagnosis of patients with SNHL in the Komfo Anokye Teaching Hospital in Ghana at the Eye Ear Nose Throat Department who were within the ages of 18 – 59 years from the period of January, 2018 to June, 2020 based on the Brighton Collaboration standard case definition. Results: Among 300 participants of this study, 165 were males and 135 females. The distributions of SNHL levels of diagnosis certainty among 300 patients according to the BC case classifications were on three classification levels; level (L1) 253 (84.3%), level 2 (L2) 2 (0.6%) and level 4 (L4) 45 (15%) respectively and out of 300, 45 cases were unclassifiable (at level 4). When separated for males and females shows that, the overall data, male patients had a lower percentage of level 1 and higher percentage of level 4 than female patients did. When patients from different sources were presented separately, the male-female differences in the distribution of diagnosis certainty level were the same for patients from Manual Data but became non-significant for patients from Electronic Data. The distributions of SNHL levels of diagnosis certainty were compared between two sources of data of patients from Manual Data had a higher percentage of level 1 and a lower percentage of level 4 than patients from Electronic Data. Conclusion: Based on the findings of this study, it is well established that, the BC standard case definition is applicable in Ghana at the tertiary hospital level. The evidence of the data indicates that, majority of the cases were diagnosis at level 1. This could mean at tertiary hospital level in Ghana and other West African countries the BC criteria can be met and majority of the diagnosis will fall within the BC standard definition. However, four out of the eight key element examinations namely; Acoustic Brainstem Response, Abnormal Otoacoustic Emission, Abnormal Behavior/Neurodevelopment Assessment, and Abnormal Remote Screening were not available, so therefore it is important for the hospital management to work towards putting infrastructure to meet such demands. Recommendations: The study suggests the BC should fund further studies to conduct evaluation of SNHL diagnosis at the district, municipal and regional hospital levels in Ghana and the other West African countries. Also, hospitals participating in Lassa fever vaccine trials should put in place systems to record cases. Moreover, physicians should ensure that patients referred to private clinics for Otoacoustic emission and Abnormal Brainstem Response examinations should bring back the reports to be entered onto the medical records. Keywords: Hearing loss, Sensorineural Hearing Loss, Lassa fever, Vaccine, Komfo Anokye Teaching Hospital. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:09:15Z (GMT). No. of bitstreams: 1 U0001-1802202116050400.pdf: 1250322 bytes, checksum: 9ff6296667e63c60fd495d5f43c42f26 (MD5) Previous issue date: 2021 | en |
dc.description.tableofcontents | Acknowledgements..................................................................i Abstract ........................................................................ii Table of Contents................................................................iv List of Tables ..................................................................vii List of Figures and Appendices .................................................viii Abbreviations.....................................................................ix Chapter 1: Background and Aims.....................................................1 1.1 Hearing loss as a Public Health Issue..........................................1 1.2 Historical Perspective of the Brighton Collaboration and Coalition for Epidemic Preparedness Innovation............................................................2 1.3 Lassa Fever Vaccine Development as an Urgent Need for Global Health............4 1.4 SNHL as a Potential Adverse Event of Lassa Fever Vaccine.......................7 1.5 Challenge in Measuring Hearing Loss ...........................................9 1.6 The Brighton Collaboration Standard Case definition for the Diagnosis of SNHL.10 1.7 Aims of the Study...........................................................12 1.8 Significance of the study...................................................12 Chapter 2: Literature Review....................................................13 2.1 Lassa fever.................................................................13 2.2 Lassa fever as a Global Public Health Problem...............................14 2.3 Sensorineural Hearing Loss in Africa and Ghana..............................17 2.4 Diagnosis of Sensorineural Hearing Loss ....................................18 Chapter 3: Methods..............................................................21 3.1 Study site .................................................................21 3.2 Study design ...............................................................21 3.3 Study Subjects .............................................................22 3.4 Sample Size estimation and final sample size................................22 3.5 Measurements................................................................23 3.6 Data Management Plan .......................................................24 3.7 Procedures of Data Extraction...............................................25 3.8 Ethics......................................................................30 3.9 Research Ownership and Achievement..........................................30 Chapter 4: Results .............................................................31 Chapter 5: Discussion ..........................................................33 5.1 Recommendations.............................................................35 5.2 Implication for Public Health...............................................35 5.3 Study Limitations...........................................................36 5.4 Conclusion .................................................................36 References......................................................................37 Appendix I: Komfo Anokye Teaching Hospital Ethics Certificate ..................57 Appendix II: National Taiwan University Hospital Ethics Certificate ............59 Appendix III ¡V Project Budget .................................................62 Appendix IV ¡V Work plan........................................................63 | |
dc.language.iso | en | |
dc.title | 加纳成人人群感觉神经性听力损失诊断的评估:一项使用布莱顿协作标准病例定义的回顾性研究 | zh_TW |
dc.title | Evaluation of Sensorineural Hearing Loss Diagnosis in the Adult Population of Ghana: A Retrospective Study Applying the Brighton Collaboration Standard Case Definition | en |
dc.type | Thesis | |
dc.date.schoolyear | 109-1 | |
dc.description.degree | 碩士 | |
dc.contributor.author-orcid | 0000-0002-9718-4189 | |
dc.contributor.coadvisor | 黃婉婷 醫師(Wan-Ting Huang) | |
dc.contributor.oralexamcommittee | 吳振吉(Chen-Chi Wu) | |
dc.subject.keyword | 耳神经性听力损失, | zh_TW |
dc.subject.keyword | Senosorineural Hearing loss,Hearing loss,Lassa fever,Vaccine,Komfo Anokye Teaching Ho, | en |
dc.relation.page | 63 | |
dc.identifier.doi | 10.6342/NTU202100744 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2021-02-20 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 全球衛生碩士/博士學位學程 | zh_TW |
顯示於系所單位: | 全球衛生學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1802202116050400.pdf 目前未授權公開取用 | 1.22 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。